Overview

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

Status:
Completed

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics and safety of dexlansoprazole, once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Dexlansoprazole
Lansoprazole